RestorEar is at the forefront of advancing clinical applications of therapeutic hypothermia to create surgical and clinical solutions for middle and inner ear disorders including noise-induced hearing loss (NIHL), tinnitus, traumatic brain injury (TBI), and relief from surgical trauma. Our products are the result of years of development effort and collaboration with our clinical partners. Partial support for our R&D and that of our collaborators comes from the National Institutes of Health, the Department of Defense, and the Department of Veterans Affairs.

TECHNOLOGY FOR IMPROVED OUTCOMES IN COCHLEAR IMPLANT SURGERY

ReSurg™ harnesses our novel cooling technology to preserve residual (“natural”) hearing function during and after cochlear implant surgery. ReSurg was developed in collaboration with leading researchers, neurotologists, and audiologists to advance patient outcomes without interfering with surgical workflow, the implant device, or patient safety. Our collaborators are currently recruiting patients for a first-in-humans clinical trial using ReSurg, set to continue through 2025.

Stay up to date on our clinical trials by visiting clinicaltrials.gov.

PROTECTION AGAINST NOISE-INDUCED HEARING LOSS

RestorEar and our collaborators have collected preliminary human data for our cutting-edge products designed to address the problems of noise-induced hearing loss and chronic tinnitus.

Our collaborators are currently working on a clinical trial using RestorEar products to explore the efficacy of cold therapy for the prevention of noise-induced hearing loss in a group of occupationally at-risk firefighters. Read more about the study at clinicaltrials.gov.

RestorEar and ReBound are FDA Registered | ReBound and ReSurg are proudly made in the USA.

RestorEar products and technologies are protected by numerous US and foreign patents, and pending patents.